Next-Generation Sequencing Implementation in a Clinical Molecular Diagnostics Laboratory

Unless otherwise noted, P.A.C.E.™ accreditation will expire six months after the live webinar.

Streamline Genetic and Molecular Testing

Next-generation sequencing (NGS) has recently emerged as a powerful tool for studying multiple genes and mutation types with a single assay. The test method lets labs use smaller tissue samples and significantly reduces the turn-around time for results.

Sentara Healthcare used NGS to help support its network of 12 hospitals and more than 200 physician offices in Virginia and North Carolina. Through test menu optimization, provider outreach, capital acquisitions, and method validation, its centralized molecular diagnostics lab insourced NGS to create efficiencies across the healthcare system.

In this P.A.C.E.-accredited Fisher Healthcare webinar, Tabetha Sundin, PhD, HCLD, MB,Sentara’s Scientific Director of Molecular Diagnostics and Serology, will discuss how the network successfully implemented NGS and streamlined testing.

Learning Objectives

This webinar will help you:

• Describe how NGS can be used to study multiple genes and mutation types in a single assay
• Explain how a molecular diagnostics lab successfully insourced NGS
• Discuss how Sentara Healthcare’s implementation of NGS helped conserve tissue, shorten turnaround times, and reduce costs

Watch On Demand      Download Presentation (PDF, 25.3MB)

This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E. Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.

Tabetha Sundin, PhD, HCLD (ABB), MB (ASCP)^CM

Dr. Sundin is the Scientific Director of Molecular Diagnostics and Serology at Sentara Healthcare. She has over 10 years of laboratory experience in cancer biology and clinical molecular diagnostics and is an active member of the Association of Molecular Pathology (AMP).

Sundin speaks about multidisciplinary facilitation of biomarker testing in cancer patients on behalf of AstraZeneca and Bristol-Myers Squibb. She’s involved with numerous efforts to support the molecular diagnostics field in collaboration with American Medical Technologists (AMT) and the Clinical & Laboratory Standards Institute (CLSI).